Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
š¹The U.S. Food and Drug Administration (FDA) has approved an injectable version of Bristol Myers Squibb’s cancer drug Opdivo, known as Opdivo Qvantig. Previously available only as an intravenous (IV) infusion, this new subcutaneous formulation offers a more convenient administration method for patients.
š¹Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system’s ability to fight cancer by removing its natural brakes.
š¹The drugmaker is relying on newer treatments like Opdivo Qvantig to drive growth as patents on older drugs, such as cancer drug Revlimid and blood thinner Eliquis, expire later this decade.
š¹Opdivo Qvantig was co-formulated with Halozyme Therapeutics’Ā drug delivery technology, which helps reduce treatment administration from hours-long IV infusions to subcutaneous injections delivered in minutes
The approval was based on data from a late-stage study, which showed that the subcutaneous form of the drug was not inferior to the intravenous formulation in patients with advanced kidney cancer who have received prior systemic therapy.
